{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:51:38Z","timestamp":1791186698584,"version":"4.1.0"},"reference-count":47,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":1618,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2008,10]]},"abstract":"<jats:p>Odiparcil is a novel, orally active \u03b2\u2010<jats:sc>d<\/jats:sc>\u2010thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events. Its unique mechanism of action is postulated by means of an elevation in circulating endogenous chondroitin sulfate\u2010related glycosaminoglycans (GAGs) levels. The purpose of these 2 separate clinical studies was to evaluate plasma GAG levels in healthy subjects administered odiparcil with either aspirin (ASA) or enoxaparin. Clinical plasma samples were processed and analyzed using validated HPLC bioassays that indirectly estimate GAG levels based on the simultaneous detection of the chondroitin disaccharide derivatives. The concomitant administration of odiparcil with or without ASA resulted in a significant elevation in GAG levels over baseline for both treatment groups. In the other clinical study, the concomitant administration of odiparcil with or without enoxaparin displayed significant increases in plasma \u0394Di\u2010OS, \u0394Di\u20104S, and total disaccharide levels versus control group. Neither plasma GAG levels nor odiparcil plasma levels were correlated with a rise in hepatic transaminases, an adverse drug event observed in several subjects; and plasma odiparcil levels were indirectly correlated with plasma GAG levels. These clinical studies were proof of concept of preclinical rat studies indicating that chronic odiparcil treatment elevates endogenous GAG levels in human subjects.<\/jats:p>","DOI":"10.1177\/0091270008323751","type":"journal-article","created":{"date-parts":[[2008,8,30]],"date-time":"2008-08-30T01:09:51Z","timestamp":1220058591000},"page":"1158-1170","source":"Crossref","is-referenced-by-count":18,"title":["Characterization of Total Plasma Glycosaminoglycan Levels in Healthy Volunteers Following Oral Administration of a Novel Antithrombotic Odiparcil With Aspirin or Enoxaparin"],"prefix":"10.1002","volume":"48","author":[{"given":"Alan L.","family":"Myers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay V.","family":"Upreti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie D.","family":"Eddington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.325.7369.887"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/107602960100700403"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1124\/pr.58.3.6"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1291"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645120-00004"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamda.2006.04.004"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1263"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200666110-00001"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.162677"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.3.271"},{"key":"e_1_2_6_12_2","first-page":"905","article-title":"BIBR\u20101048 Boehringer Ingelheim","volume":"3","author":"Mungall D","year":"2002","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm050101d"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064247"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2005.11.047"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1055\/s-0037-1614604","article-title":"Further studies on the mechanism for the antithrombotic effects of naroparcil, an orally active thioxyloside compound","volume":"81","author":"Masson P","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.6.2662"},{"key":"e_1_2_6_18_2","first-page":"313","article-title":"The beneficial effect of a beta\u2010D\u2010xyloside, Iliparcil, in the prevention of postthrombolytic rethrombosis in the rat","volume":"28","author":"Chicaud P","year":"1998","journal-title":"Haemostasis"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02064.x"},{"key":"e_1_2_6_20_2","first-page":"209","volume-title":"Biochemistry","author":"Garrett RH","year":"1999"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1006\/abio.2001.5545"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(77)90500-9"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(82)90273-0"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000090673.96120.67"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2005.02.008"},{"issue":"1","key":"e_1_2_6_26_2","first-page":"9","article-title":"Structural features and binding properties of chondroitin sulfates, dermatan sulfate, and heparan sulfate","volume":"17","author":"Casu B","year":"1991","journal-title":"Semin Thromb Hemost"},{"key":"e_1_2_6_27_2","first-page":"459","article-title":"Dermatan sulfate as a potential antithrombotic drug","volume":"72","author":"Pangrazzi J","year":"1987","journal-title":"Haematologica"},{"key":"e_1_2_6_28_2","unstructured":"DubbJW HendersonLS OkadaSS PeyrouV SamuelsRE ShethS SperaPA ToomeyJR WilsonD inventors. Glaxo Group Limited Laboratories Fournier S.A. Dubb JW Henderson LS Okada SS Peyrou V Samuels RE Sheth S Spera PA Toomey JR Wilson D assignees.Methods of Treatment and Prevention. International Patent WO\/2006\/060647.August 6 2006."},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0008-6215(88)80045-4"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.3_suppl.204S"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12266"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-999015"},{"key":"e_1_2_6_33_2","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1016\/S0021-9258(19)41195-2","article-title":"Stimulation of synthesis of free chondroitin sulfate chains by beta\u2010D\u2010xylosides in cultured cells","volume":"250","author":"Galligani L","year":"1975","journal-title":"J Biol Chem"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-440X(00)00125-1"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjsm.2002.001388"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1006\/abio.2002.5708"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199405053301808"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.1_suppl.64S"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/01926230590522121"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.1.108.34436"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1177\/00912700122010465"},{"key":"e_1_2_6_42_2","first-page":"146","article-title":"Postheparin plasma lipoprotein lipase and hepatic lipase in normal human subjects: relationship to age, sex and triglyceride metabolism","volume":"82","author":"Huttunen JK","year":"1977","journal-title":"Adv Exp Med Biol"},{"key":"e_1_2_6_43_2","first-page":"1133","article-title":"Hypertransaminasemia with subcutaneous heparin therapy","volume":"17","author":"Shilo S","year":"1981","journal-title":"Isr J Med Sci"},{"key":"e_1_2_6_44_2","first-page":"1663","volume-title":"Harrison's Principles of Internal Medicine","author":"Podolsky DK","year":"1998"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.155"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0968-0004(88)90088-6"},{"key":"e_1_2_6_47_2","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1042\/bst0190866","article-title":"Structure and properties of dermatan sulphate proteoglycans","volume":"19","author":"Coster L","year":"1991","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"e_1_2_6_48_2","first-page":"199","article-title":"A survey of the clinical experience with dermatan sulfate","volume":"17","author":"Gianese F","year":"1991","journal-title":"Semin Thromb Hemost"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270008323751","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270008323751","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T21:43:05Z","timestamp":1697146985000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270008323751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1177\/0091270008323751"],"URL":"https:\/\/doi.org\/10.1177\/0091270008323751","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}